Abstract
The NF1 gene, a putative tumor suppressor gene, contains a GAP related domain (GRD) which accelerates hydrolysis of ras-bound GTP to GDP, thereby converting the ras oncogene from its active to inactive form. Two forms of the NF1 GRD transcript (Type I and Type II) are differentially expressed in neuroectodermal tumor tissue relative to differentiated neural cells, and in gastric cancer cell lines relative to normal stomach mucosa. We measured relative expression of NF1 Type II and Type I isoforms in cultured normal and malignant human ovarian surface epithelial cells(HOSE) and in invasive and borderline ovarian tumor tissue. We demonstrated an 11-fold increase in Type II: Type I ratio in 7 HOSE cultures relative to eight ovarian cancer cell lines. Our findings indicate a significant decrease in Type II isoform expression and increase in Type I expression in ovarian cancer cells and tumor tissue relative to HOSE cells. We also demonstrate an increase in Type II: Type I ratio, and a decrease in cell proliferation rate in three ovarian cancer cell lines on treatment with retinoic acid. We propose that differential expression of the NF1 Type I and Type II isoforms is related to cellular differentiation in ovarian epithelial cancer and strategies based on alteration in NF1 isoform expression may have thera-peutic potential in ovarian malignancies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Al-Alawi N, Xu G, White R, Clark R, McCormick R and Feramisco JR. . 1993 Mol. Cell. Biol. 13: 2497–2503.
Andersen LB, Ballester R, Marchuk DA, Chang E, Gutmann DH, Saulino AM, Camonis J, Wigler M and Collins FS. . 1993 Mol. Cell. Biol. 13: 487–495.
Auersperg N, Edelson MI, Mok SC, Johnson SW and Hamilton TC. . 1998 Semin. Oncol. 25: 281–304.
Azuma M, Kawamata H, Kasai Y, Nagamine S, Yoshida H, Yanagawa T and Sato M. . 1988 Cancer Res. 48: 7219–7225.
Barker D, Wright E, Nguyen K, Cannon L, Fain P, Goldgar D, Bishop DT, Carey J, Baty B, Kivlin J, Willard H, Waye JS, Greig G, Leinwand L, Nakamura Y, O'Connell P, Leppert M, Lalouel JM, White R and Skolnick M. . 1997 Science 236: 1100–1102.
Brooks SE, Timmerman J, Lau CC, Tsao SW, Knapp RC and Sheets EE. . 1991 Gynecol. Oncol. 42: 265–272.
Caliaro MJ, Marmouget C, Guichard S, Mazars P, Valette A, Moisand A, Bugat R and Jozan S. . 1994 Int. J. Cancer 56: 743–748.
Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Keeney G, Podratz KC and Jenkins R. . 1993 Cancer Res. 53: 2393–2398.
DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC and Lowy DR. . 1992 Cell 69: 265–273.
Goldgar DE, Green P, Parry DM and Mulvihill JJ. . 1987 Am. J. Hum. Genet. 44: 6–12.
Gutmann DH, Tennekoon GI, Cole JL, Collins FS and Rutkowski JL. . 1993 J. Neurosci Res. 36: 216–223.
Harant H, Korschinieck I, Krupitza G, Fazeny B, Dittrich C and Grunt TW. . 1993 Br. J. Cancer 68: 530–536.
International Federation of Gynecology and Obstetrics: Changes in Definition of Clinical Staging for Carcinoma of the Cervix and Ovary. . 1987 Am. J. Obstet. Gynecol. 156: 263–264.
Iyengar TD, Berkowitz RS and Mok SC. . 1996 Gynecol. Oncol. 60: 114–115.
Jing Y, Waxman S and Mira-y-Lopez R. . 1997 Cancer Res. 57: 1668–1672.
Langdon SP, Hawkes MM, Hay FG, Lawrie SS, Schol DJ, Hilgers J, Leonard RCF and Smythe JF. . 1988 Cancer Res. 48: 6161–6165.
Lu KH, Weitzel JN, Kodali S, Welch WR, Berkowitz RS and Mok SC. . 1997 Cancer Res. 57: 387–390.
Marchuk DA, Saulino AM, Tavakkol R, Swaroop M, Wallace MR, Andersen LB, Mitchell AL, Gutmann DH, Boguski M and Collins FS. . 1991 Genomics 11: 931–940.
Mazars R, Pujol P, Maudelonde T, Jeanteur P and Theillet C. . 1991 Oncogene 6: 1685–1690.
Martin GA, Viskochil D, Boilag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O'Connell P, Cawthon RM, Innis MA and McCormick F. . 1990 Cell 63: 643–649.
McCormick F, Adari H, Trahey M, Halenbeck R, Koths K, Martin GZ, Crosier WJ, Watt K, Rubinfeld B and Wong G. . 1988 Cold Spring Harb. Symp. Quant. Biol. 53: 849–854.
Nakafuku M, Nagamine M, Ohtoshi A, Tanaka K, Toh-EA and Kaziro Y. . 1993 Proc. Natl. Acad. Sci. 90: 6706–6710.
Nishi T, Lee PS, Oka K, Levin VA, Tanase S, Morino Y and Saya H. . 1991 Oncogene 6: 1555–1559.
Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbrueck T, Xynos FP and Donis-Keller H. . 1996 Cancer Res. 56: 606–611.
Reese DH, Gordon B, Gratzner HG, Claflin AJ, Malinin TI, Block NL and Pilitano VA. . 1983 Cancer Res. 43: 5443–5450.
Riccardi VM. . 1981 Advances in Neurology. vol. 29: Neurofibromatosis (von Recklinghsusen Disease. Riccardi VM and Mulvihill JJ. (eds) Raven Press: New York.
Rodabaugh KJ, Blanchard G, Welch WR, Bell DA, Berkowitz RS and Mok SC. . 1995 Cancer Res. 55: 2169–2172.
Sato T, Saito H, Morita R, Koi S, Lee JH and Nakamura Y. . 1991 Cancer Res. 51: 5118–5122.
Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Fanjniarz AG, Chau MV, Huson S, Korf BR, Parry DM, Pericak-Vance MA, Collins FS, Hobbs WJ, Falcone BG, Iannazzi JA, Roy JC, St. George-Hyslop PH, Tanzi RE, Bothwell MA, Upadhyaya M, Harper P, Goldstein AE, Hoover DL, Bader JL, Spence MA, Mulvihill JJ, Aylsworth AS, Vance JM, Rossenwasser GOD, Gaskell PC, Roses AD, Martuza RL, Breakefield XP and Gusella JF. . 1987 Cell 49: 589–594.
Skuse GR and Ludlow JW. . 1995 Lancet 345: 902–906.
Sidell N and Koeffler PH. . 1988 Cancer Res. 48: 2226–2230.
Tanaka K, Nakafuku M, Tamanoi F, Kaziro Y, Matsumoto K and Toh-E A. . 1990 Mol. Cell. Biol. 10: 4303–4313.
Tangir J, Loughridge NS, Berkowitz RS, Muto MG, Bell DA, Welch WR and Mok SC. . 1996 Cancer Res. 56: 2501–2505.
Tsao S, Mok SC, Fey EG, Fletcher JA, Wan TS, Chew E, Muto MG, Knapp RC and Berkowitz RS. . 1995 Exp. Cell Res. 218: 499–507.
Uchida T, Matozaki T, Suzuki T, Matsuda K, Wada K, Nakano O, Konda Y, Nishisaki H, Nagao M, Sakamoto C and Kasuga M. . 1992 Biochem. Biophys. Res. Commun. 187: 332–339.
Vogel US, Dixon RA, Schaber MD, Diehl RE, Marshall MS, Scolnick EM, Sigal IS and Gibbs JB. . 1988 Nature 335: 90–93.
Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL, Brownstein BH and Collins FS. . 1990 Science 249: 181–186.
Wertheim I, Tangir J, Muto MG, Welch WR, Berkowitz RS, Chen WY and Mok SC. . 1996 Oncogene 12: 2147–2153.
Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS and Mok SC. . 1994 J. Natl. Cancer Inst. 86: 1549–1551.
Xu G, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R and Weiss R. . 1990 Cell 62: 599–608.
Acknowledgements
This work was supported in part by Public Health Service Grants R29CA70216, RO1CA63381, R01CA69453, RO1CA69291, RO1CA78523 from the National Institute of Health, Department of Health and Human Services.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Iyengar, T., Ng, Sw., Lau, C. et al. Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors. Oncogene 18, 257–262 (1999). https://doi.org/10.1038/sj.onc.1202294
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202294